Foghorn Therapeutics Inc (FHTX) Stock Price, Quote & News

Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-ce...

Industry: Biotechnology

Sector: Healthcare

Phone: 617-586-3100

Website: foghorntx.com

Address:

99 Coolidge Avenue, Suite 500, Watertown, United States

Orlandotrader May. 8 at 7:49 PM

$FHTX New position Today. A bit early but let’s Rock.

0 · Reply

BillionerOfKing May. 5 at 12:40 PM

$FHTX Current Stock Price: $4.68 Contracts to trade: $5.0 FHTX May 15 2026 Call Entry: $0.63 Exit: $1.02 ROI: 61% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday May. 4 at 9:18 PM

$FHTX Share Price: $4.68 Contract Selected: Dec 18, 2026 $7.5 Calls Buy Zone: $0.96 – $1.18 Target Zone: $1.67 – $2.04 Potential Upside: 65% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

focafoca99 Apr. 21 at 8:47 PM

$FHTX showed new preclinical data across several programs, including complete and durable tumor regression for FHD-909 in combination with anti-PD-1 in mouse models.

0 · Reply

focafoca99 Apr. 9 at 7:53 PM

$FHTX will present new preclinical AACR data on FHD-909 and several degrader programs.

0 · Reply

StocktwitsEarnings Mar. 12 at 1:00 AM

$FHTX Q4 '25 Earnings Results & Recap Foghorn Therapeutics Inc. expects its cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures for at least twelve months, with $249.2M in deferred revenue expected through 2029 or beyond.

0 · Reply

d_risk Mar. 12 at 12:32 AM

$FHTX - Foghorn Therapeutics Inc - 10K - Updated Risk Factors FHTX flags new risks from AI/ML use, shifting federal healthcare and FDA policies (including post-Loper regulatory uncertainty and IRA implementation), and political/administrative changes that could slow approvals, raise compliance costs, and pressure pricing, while dropping emerging-growth-company status as a distinct risk. #Biotechnology #AIMLIntegration #HealthcareRegulation #FDAApproval #PricingPressure 🟢 Added 🟠 Removed https://d-risk.ai/FHTX/10-K/2026-03-11

0 · Reply

Abron Mar. 9 at 3:51 PM

$FHTX Every day the same tning

0 · Reply

NorthStarStats Mar. 8 at 4:39 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $KR Score:90.00 (BREAKOUT WATCH), $SLDB Score: 95.00; MDA Conf.,Earnings,Phase 3 Trial, $GHRS Score: 95.00; Phase 3 Start Announcement, $FHTX Score: 85.00;Cash Runaway, $SBUX Score 70.00; Revenue +6% 600-650 new stores

0 · Reply

Abron Feb. 26 at 3:33 PM

$FHTX every day same thing

0 · Reply

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

2026-05-07T15:01:40.000Z - 5 days ago

Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)

May 7, 2026, 7:00 AM EDT - 6 days ago

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

2026-04-21T21:02:02.000Z - 21 days ago

Foghorn Therapeutics presents new preclinical data for FHD-909

Apr 21, 2026, 4:05 PM EDT - 21 days ago

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Apr 9, 2026, 7:00 AM EDT - 4 weeks ago

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Mar 11, 2026, 4:09 PM EDT - 2 months ago

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Mar 3, 2026, 11:10 AM EST - 2 months ago

Foghorn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 7:00 AM EST - 2 months ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

2026-02-23T12:13:58.000Z - 2 months ago

Foghorn Therapeutics appoints Maynard as Chief Financial Officer

Feb 23, 2026, 7:00 AM EST - 2 months ago

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

2026-02-17T11:21:35.000Z - 3 months ago

Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies

Feb 11, 2026, 3:00 PM EST - 3 months ago

Foghorn Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 7:00 AM EST - 3 months ago

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

Jan 13, 2026, 4:05 PM EST - 4 months ago

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

Jan 9, 2026, 10:20 PM EST - 4 months ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

2025-12-18T11:55:21.000Z - 5 months ago

Foghorn Therapeutics initiated with a Buy at BTIG

Dec 4, 2025, 9:10 AM EST - 5 months ago

Foghorn Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-12-03T21:20:41.000Z - 5 months ago

Foghorn Therapeutics initiated with a Buy at Stifel

LLY

Nov 25, 2025, 7:00 AM EST - 6 months ago

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 19, 2025, 5:30 AM EST - 6 months ago

Foghorn Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 11:00 AM EST - 6 months ago

Foghorn Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-07T11:30:50.000Z - 6 months ago

Foghorn Therapeutics initiated with a Buy at Guggenheim

2025-11-05T12:06:26.000Z - 6 months ago

Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)

Nov 5, 2025, 7:00 AM EST - 6 months ago

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

Nov 3, 2025, 7:30 AM EST - 6 months ago

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Oct 30, 2025, 12:00 PM EDT - 6 months ago

Foghorn Therapeutics Transcript: 8th Annual Targeted Protein Degradation & Induced Proximity Summit

2025-10-30T11:41:51.000Z - 6 months ago

Foghorn announces updates for Selective ARID1B, Selective CBP, Selective EP300

Oct 30, 2025, 7:30 AM EDT - 6 months ago

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

2025-10-16T11:10:48.000Z - 7 months ago

Foghorn Therapeutics announces progress for Selective ARID1B degrader program

Oct 16, 2025, 7:00 AM EDT - 7 months ago

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

2025-09-17T12:40:20.000Z - 8 months ago

Foghorn Therapeutics transferred with Buy rating at B. Riley

Aug 28, 2025, 8:00 AM EDT - 9 months ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

IQV MRNA SANA

2025-08-05T14:45:31.000Z - 10 months ago

Foghorn Therapeutics management to meet virtually with B. Riley

2025-08-05T11:16:10.000Z - 10 months ago

Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

Jun 5, 2025, 3:45 PM EDT - 1 year ago

Foghorn Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

2025-05-14T11:06:24.000Z - 1 year ago

Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)

2025-05-14T11:06:16.000Z - 1 year ago

Foghorn Therapeutics sees cash runway into 2027

May 14, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

May 5, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

2025-05-01T11:41:55.000Z - 1 year ago

Foghorn Therapeutics appoints Neil Gallagher, Stuart Duty to board

May 1, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Transcript: AACR Annual Meeting 2025

2025-04-28T20:45:06.000Z - 1 year ago

Foghorn Therapeutics announces new preclinical data at AACR

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

2025-04-23T09:35:31.000Z - 1 year ago

Foghorn Therapeutics initiated with an Outperform at Citizens JMP

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Mar 25, 2025, 4:35 PM EDT - 1 year ago

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Mar 6, 2025, 4:05 PM EST - 1 year ago

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

Mar 3, 2025, 2:30 PM EST - 1 year ago

Foghorn Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Dec 16, 2024, 7:00 AM EST - 1 year ago

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

Dec 3, 2024, 1:20 PM EST - 1 year ago

Foghorn Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 7:00 AM EST - 1 year ago

Foghorn Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Foghorn Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

May 28, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

May 22, 2024, 6:21 PM EDT - 2 years ago

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

May 20, 2024, 7:58 AM EDT - 2 years ago

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

May 6, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Foghorn Therapeutics Transcript: Status Update

Apr 9, 2024, 4:30 PM EDT - 2 years ago

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Apr 5, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 2 years ago

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Mar 7, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Mar 5, 2024, 4:48 PM EST - 2 years ago

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Feb 28, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

Dec 1, 2023, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Oct 13, 2023, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Sep 11, 2023, 6:30 AM EDT - 2 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

DNLI MCRB MRNA SANA

$Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML$

Aug 31, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

Aug 4, 2023, 7:00 AM EDT - 3 years ago

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

Orlandotrader May. 8 at 7:49 PM

$FHTX New position Today. A bit early but let’s Rock.

0 · Reply

BillionerOfKing May. 5 at 12:40 PM

0 · Reply

SuperGreenToday May. 4 at 9:18 PM

0 · Reply

focafoca99 Apr. 21 at 8:47 PM

$FHTX showed new preclinical data across several programs, including complete and durable tumor regression for FHD-909 in combination with anti-PD-1 in mouse models.

0 · Reply

focafoca99 Apr. 9 at 7:53 PM

$FHTX will present new preclinical AACR data on FHD-909 and several degrader programs.

0 · Reply

StocktwitsEarnings Mar. 12 at 1:00 AM

0 · Reply

d_risk Mar. 12 at 12:32 AM

0 · Reply

Abron Mar. 9 at 3:51 PM

$FHTX Every day the same tning

0 · Reply

NorthStarStats Mar. 8 at 4:39 PM

0 · Reply

Abron Feb. 26 at 3:33 PM

$FHTX every day same thing

0 · Reply

BioTuesdays Feb. 23 at 2:51 PM

$FHTX has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today. https://biotuesdays.com/2026/02/23/foghorn-appoints-ryan-maynard-as-cfo/

0 · Reply

OfficialStocktwitsUser Feb. 22 at 11:51 PM

$FHTX RSI: 50.43, MACD: 0.0250 Vol: 0.20, MA20: 5.65, MA50: 5.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 10 at 11:36 PM

$FHTX Current Stock Price: $5.45 Contracts to trade: $5.0 FHTX Feb 20 2026 Call Entry: $2.21 Exit: $4.27 ROI: 93% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

wyoming2020 Feb. 7 at 12:27 PM

$FHTX CEO big buy at Foghorn $ACIU $PDSB fam check it out

0 · Reply

kimmynjgrl Feb. 3 at 11:19 PM

$FHTX One min video... https://youtube.com/shorts/tLWJo9AlexE?feature=share

0 · Reply

vu_jade Feb. 2 at 4:21 PM

$FHTX get your Foghorn LEG”horn” up

0 · Reply

vu_jade Jan. 28 at 8:31 PM

$FHTX ADDED

0 · Reply

SuperGreenToday Jan. 24 at 2:08 PM

$FHTX Share Price: $5.87 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.23 – $1.52 Target Zone: $2.14 – $2.61 Potential Upside: 64% ROI Time to Expiration: 144 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

vu_jade Jan. 21 at 8:43 PM

$FHTX great set up

0 · Reply

oneyedjacks Jan. 12 at 8:29 PM

$FHTX I Say I say Bullish

1 · Reply

vu_jade Jan. 12 at 7:46 PM

$FHTX howdy

0 · Reply

LabPsycho Jan. 12 at 6:50 PM

$FHTX $PRLD @Stmkr mysteriously prld pause smarca2 = 100% price increase. Something else seems to be going on? I've posted my conspiracy theories for rebuking. Worst part is all the time I wasted creating a simulation with their molecule. Maybe I should work on a molecular model for FHTX...however such a huge time and effort drain in the research and set up required to get one to work and hardly anyone seems to care about these molecular dynamic simulations I post. Hmm...what to do?

1 · Reply

Market Cap	254.23M
Revenue (ttm)	30.91M
Net Income (ttm)	-74.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-240.31%
Debt to Equity Ratio	0.00

Volume	183,700
Avg Vol	155,986
Day's Range	N/A - N/A
Shares Out	58.71M
Stochastic %K	23%
Beta	2.97
Analysts	Strong Sell
Price Target	$11.44